Scleroderma Diagnostics and Therapeutics Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Type (Localized Scleroderma, Systemic Scleroderma); Diagnosis (Antibodies Tests, Capillaroscopy, Cardiac Diagnosis, Gastrointestinal Diagnosis, Imaging, Pulmonary Diagnosis, Skin Viscoelasticity, General); Drug Class (Corticosteroids, Immunosuppressive Agents, Endothelin Receptor Antagonists, Calcium Channel Blockers, PDE-5 Inhibitors, Chelating Agents, Prostacyclin Analogues, Others), and Geography

Report Code: TIPRE00019755 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
Covid
MARKET INTRODUCTION

Scleroderma is a rare, auto-immune, and long-lasting disease that affects the skin, connective tissue, and internal organs. It is caused due to excessive production of the protein collagen, which results in skin tightening and thickening. It may result in scar formation on the lungs and kidneys.

MARKET DYNAMICS

The scleroderma diagnostics and therapeutics market growth is estimated to grow due to growing genetic variation, increasing scleroderma incidences, and rising development in diagnostic and therapeutic technologies. The market is likely to have growth opportunities due to continuous research and developments for scleroderma diagnosis and therapeutics.

MARKET SCOPE

The "Scleroderma Diagnostics and Therapeutics Market Analysis to 2027" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of scleroderma diagnostics and therapeutics market with detailed market segmentation by type, diagnosis and drug class. The scleroderma diagnostics and therapeutics market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in scleroderma diagnostics and therapeutics market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The scleroderma diagnostics and therapeutics market is segmented on the basis of type, diagnosis and drug class. Based on type, the market is classified as localized scleroderma, and systemic scleroderma. On the basis of diagnosis, the market is segmented as for antibodies tests, capillaroscopy, cardiac diagnosis, gastrointestinal diagnosis, imaging, pulmonary diagnosis, skin viscoelasticity, and general.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the scleroderma diagnostics and therapeutics market based on various segments. It also provides market size and forecast estimates from year 2019 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The scleroderma diagnostics and therapeutics market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting scleroderma diagnostics and therapeutics market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the scleroderma diagnostics and therapeutics market in these regions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the scleroderma diagnostics and therapeutics market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from scleroderma diagnostics and therapeutics market are anticipated to have lucrative growth opportunities in the future with the rising demand for scleroderma diagnostics and therapeutics market in the global market. Below mentioned is the list of few companies engaged in the scleroderma diagnostics and therapeutics market.

The report also includes the profiles of key players in scleroderma diagnostics and therapeutics market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  •  F. Hoffmann La Roche Ltd.
  •  Merck KGaA
  •  Pfizer, Inc.
  •  Bayer AG
  •  Bristol-Myers Squibb
  •  BioLineRx, Ltd.
  •  Active Biotech AB
  •  Angion Biomedica
  •  QIAGEN N.V.
  •  Actelion Pharmaceuticals, Inc.

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Scleroderma Diagnostics And Therapeutics Market - By Type
1.3.2 Scleroderma Diagnostics And Therapeutics Market - By Diagnosis
1.3.3 Scleroderma Diagnostics And Therapeutics Market - By Drug Class
1.3.4 Scleroderma Diagnostics And Therapeutics Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. SCLERODERMA DIAGNOSTICS AND THERAPEUTICS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. SCLERODERMA DIAGNOSTICS AND THERAPEUTICS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. SCLERODERMA DIAGNOSTICS AND THERAPEUTICS MARKET - GLOBAL MARKET ANALYSIS
6.1. SCLERODERMA DIAGNOSTICS AND THERAPEUTICS - GLOBAL MARKET OVERVIEW
6.2. SCLERODERMA DIAGNOSTICS AND THERAPEUTICS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. SCLERODERMA DIAGNOSTICS AND THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - TYPE
7.1. OVERVIEW
7.2. TYPE MARKET FORECASTS AND ANALYSIS
7.3. LOCALIZED SCLERODERMA
7.3.1. Overview
7.3.2. Localized Scleroderma Market Forecast and Analysis
7.4. SYSTEMIC SCLERODERMA
7.4.1. Overview
7.4.2. Systemic Scleroderma Market Forecast and Analysis
8. SCLERODERMA DIAGNOSTICS AND THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - DIAGNOSIS
8.1. OVERVIEW
8.2. DIAGNOSIS MARKET FORECASTS AND ANALYSIS
8.3. ANTIBODIES TESTS
8.3.1. Overview
8.3.2. Antibodies Tests Market Forecast and Analysis
8.4. CAPILLAROSCOPY
8.4.1. Overview
8.4.2. Capillaroscopy Market Forecast and Analysis
8.5. CARDIAC DIAGNOSIS
8.5.1. Overview
8.5.2. Cardiac Diagnosis Market Forecast and Analysis
8.6. GASTROINTESTINAL DIAGNOSIS
8.6.1. Overview
8.6.2. Gastrointestinal Diagnosis Market Forecast and Analysis
8.7. IMAGING
8.7.1. Overview
8.7.2. Imaging Market Forecast and Analysis
8.8. PULMONARY DIAGNOSIS
8.8.1. Overview
8.8.2. Pulmonary Diagnosis Market Forecast and Analysis
8.9. SKIN VISCOELASTICITY
8.9.1. Overview
8.9.2. Skin Viscoelasticity Market Forecast and Analysis
8.10. GENERAL
8.10.1. Overview
8.10.2. General Market Forecast and Analysis
9. SCLERODERMA DIAGNOSTICS AND THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - DRUG CLASS
9.1. OVERVIEW
9.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
9.3. CORTICOSTEROIDS
9.3.1. Overview
9.3.2. Corticosteroids Market Forecast and Analysis
9.4. IMMUNOSUPPRESSIVE AGENTS
9.4.1. Overview
9.4.2. Immunosuppressive Agents Market Forecast and Analysis
9.5. ENDOTHELIN RECEPTOR ANTAGONISTS
9.5.1. Overview
9.5.2. Endothelin Receptor Antagonists Market Forecast and Analysis
9.6. CALCIUM CHANNEL BLOCKERS
9.6.1. Overview
9.6.2. Calcium Channel Blockers Market Forecast and Analysis
9.7. PDE-5 INHIBITORS
9.7.1. Overview
9.7.2. PDE-5 Inhibitors Market Forecast and Analysis
9.8. CHELATING AGENTS
9.8.1. Overview
9.8.2. Chelating Agents Market Forecast and Analysis
9.9. PROSTACYCLIN ANALOGUES
9.9.1. Overview
9.9.2. Prostacyclin Analogues Market Forecast and Analysis
9.10. OTHERS
9.10.1. Overview
9.10.2. Others Market Forecast and Analysis
10. SCLERODERMA DIAGNOSTICS AND THERAPEUTICS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Scleroderma Diagnostics And Therapeutics Market Overview
10.1.2 North America Scleroderma Diagnostics And Therapeutics Market Forecasts and Analysis
10.1.3 North America Scleroderma Diagnostics And Therapeutics Market Forecasts and Analysis - By Type
10.1.4 North America Scleroderma Diagnostics And Therapeutics Market Forecasts and Analysis - By Diagnosis
10.1.5 North America Scleroderma Diagnostics And Therapeutics Market Forecasts and Analysis - By Drug Class
10.1.6 North America Scleroderma Diagnostics And Therapeutics Market Forecasts and Analysis - By Countries
10.1.6.1 United States Scleroderma Diagnostics And Therapeutics Market
10.1.6.1.1 United States Scleroderma Diagnostics And Therapeutics Market by Type
10.1.6.1.2 United States Scleroderma Diagnostics And Therapeutics Market by Diagnosis
10.1.6.1.3 United States Scleroderma Diagnostics And Therapeutics Market by Drug Class
10.1.6.2 Canada Scleroderma Diagnostics And Therapeutics Market
10.1.6.2.1 Canada Scleroderma Diagnostics And Therapeutics Market by Type
10.1.6.2.2 Canada Scleroderma Diagnostics And Therapeutics Market by Diagnosis
10.1.6.2.3 Canada Scleroderma Diagnostics And Therapeutics Market by Drug Class
10.1.6.3 Mexico Scleroderma Diagnostics And Therapeutics Market
10.1.6.3.1 Mexico Scleroderma Diagnostics And Therapeutics Market by Type
10.1.6.3.2 Mexico Scleroderma Diagnostics And Therapeutics Market by Diagnosis
10.1.6.3.3 Mexico Scleroderma Diagnostics And Therapeutics Market by Drug Class
10.2. EUROPE
10.2.1 Europe Scleroderma Diagnostics And Therapeutics Market Overview
10.2.2 Europe Scleroderma Diagnostics And Therapeutics Market Forecasts and Analysis
10.2.3 Europe Scleroderma Diagnostics And Therapeutics Market Forecasts and Analysis - By Type
10.2.4 Europe Scleroderma Diagnostics And Therapeutics Market Forecasts and Analysis - By Diagnosis
10.2.5 Europe Scleroderma Diagnostics And Therapeutics Market Forecasts and Analysis - By Drug Class
10.2.6 Europe Scleroderma Diagnostics And Therapeutics Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Scleroderma Diagnostics And Therapeutics Market
10.2.6.1.1 Germany Scleroderma Diagnostics And Therapeutics Market by Type
10.2.6.1.2 Germany Scleroderma Diagnostics And Therapeutics Market by Diagnosis
10.2.6.1.3 Germany Scleroderma Diagnostics And Therapeutics Market by Drug Class
10.2.6.2 France Scleroderma Diagnostics And Therapeutics Market
10.2.6.2.1 France Scleroderma Diagnostics And Therapeutics Market by Type
10.2.6.2.2 France Scleroderma Diagnostics And Therapeutics Market by Diagnosis
10.2.6.2.3 France Scleroderma Diagnostics And Therapeutics Market by Drug Class
10.2.6.3 Italy Scleroderma Diagnostics And Therapeutics Market
10.2.6.3.1 Italy Scleroderma Diagnostics And Therapeutics Market by Type
10.2.6.3.2 Italy Scleroderma Diagnostics And Therapeutics Market by Diagnosis
10.2.6.3.3 Italy Scleroderma Diagnostics And Therapeutics Market by Drug Class
10.2.6.4 Spain Scleroderma Diagnostics And Therapeutics Market
10.2.6.4.1 Spain Scleroderma Diagnostics And Therapeutics Market by Type
10.2.6.4.2 Spain Scleroderma Diagnostics And Therapeutics Market by Diagnosis
10.2.6.4.3 Spain Scleroderma Diagnostics And Therapeutics Market by Drug Class
10.2.6.5 United Kingdom Scleroderma Diagnostics And Therapeutics Market
10.2.6.5.1 United Kingdom Scleroderma Diagnostics And Therapeutics Market by Type
10.2.6.5.2 United Kingdom Scleroderma Diagnostics And Therapeutics Market by Diagnosis
10.2.6.5.3 United Kingdom Scleroderma Diagnostics And Therapeutics Market by Drug Class
10.2.6.6 Rest of Europe Scleroderma Diagnostics And Therapeutics Market
10.2.6.6.1 Rest of Europe Scleroderma Diagnostics And Therapeutics Market by Type
10.2.6.6.2 Rest of Europe Scleroderma Diagnostics And Therapeutics Market by Diagnosis
10.2.6.6.3 Rest of Europe Scleroderma Diagnostics And Therapeutics Market by Drug Class
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Scleroderma Diagnostics And Therapeutics Market Overview
10.3.2 Asia-Pacific Scleroderma Diagnostics And Therapeutics Market Forecasts and Analysis
10.3.3 Asia-Pacific Scleroderma Diagnostics And Therapeutics Market Forecasts and Analysis - By Type
10.3.4 Asia-Pacific Scleroderma Diagnostics And Therapeutics Market Forecasts and Analysis - By Diagnosis
10.3.5 Asia-Pacific Scleroderma Diagnostics And Therapeutics Market Forecasts and Analysis - By Drug Class
10.3.6 Asia-Pacific Scleroderma Diagnostics And Therapeutics Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Scleroderma Diagnostics And Therapeutics Market
10.3.6.1.1 Australia Scleroderma Diagnostics And Therapeutics Market by Type
10.3.6.1.2 Australia Scleroderma Diagnostics And Therapeutics Market by Diagnosis
10.3.6.1.3 Australia Scleroderma Diagnostics And Therapeutics Market by Drug Class
10.3.6.2 China Scleroderma Diagnostics And Therapeutics Market
10.3.6.2.1 China Scleroderma Diagnostics And Therapeutics Market by Type
10.3.6.2.2 China Scleroderma Diagnostics And Therapeutics Market by Diagnosis
10.3.6.2.3 China Scleroderma Diagnostics And Therapeutics Market by Drug Class
10.3.6.3 India Scleroderma Diagnostics And Therapeutics Market
10.3.6.3.1 India Scleroderma Diagnostics And Therapeutics Market by Type
10.3.6.3.2 India Scleroderma Diagnostics And Therapeutics Market by Diagnosis
10.3.6.3.3 India Scleroderma Diagnostics And Therapeutics Market by Drug Class
10.3.6.4 Japan Scleroderma Diagnostics And Therapeutics Market
10.3.6.4.1 Japan Scleroderma Diagnostics And Therapeutics Market by Type
10.3.6.4.2 Japan Scleroderma Diagnostics And Therapeutics Market by Diagnosis
10.3.6.4.3 Japan Scleroderma Diagnostics And Therapeutics Market by Drug Class
10.3.6.5 South Korea Scleroderma Diagnostics And Therapeutics Market
10.3.6.5.1 South Korea Scleroderma Diagnostics And Therapeutics Market by Type
10.3.6.5.2 South Korea Scleroderma Diagnostics And Therapeutics Market by Diagnosis
10.3.6.5.3 South Korea Scleroderma Diagnostics And Therapeutics Market by Drug Class
10.3.6.6 Rest of Asia-Pacific Scleroderma Diagnostics And Therapeutics Market
10.3.6.6.1 Rest of Asia-Pacific Scleroderma Diagnostics And Therapeutics Market by Type
10.3.6.6.2 Rest of Asia-Pacific Scleroderma Diagnostics And Therapeutics Market by Diagnosis
10.3.6.6.3 Rest of Asia-Pacific Scleroderma Diagnostics And Therapeutics Market by Drug Class
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Scleroderma Diagnostics And Therapeutics Market Overview
10.4.2 Middle East and Africa Scleroderma Diagnostics And Therapeutics Market Forecasts and Analysis
10.4.3 Middle East and Africa Scleroderma Diagnostics And Therapeutics Market Forecasts and Analysis - By Type
10.4.4 Middle East and Africa Scleroderma Diagnostics And Therapeutics Market Forecasts and Analysis - By Diagnosis
10.4.5 Middle East and Africa Scleroderma Diagnostics And Therapeutics Market Forecasts and Analysis - By Drug Class
10.4.6 Middle East and Africa Scleroderma Diagnostics And Therapeutics Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Scleroderma Diagnostics And Therapeutics Market
10.4.6.1.1 South Africa Scleroderma Diagnostics And Therapeutics Market by Type
10.4.6.1.2 South Africa Scleroderma Diagnostics And Therapeutics Market by Diagnosis
10.4.6.1.3 South Africa Scleroderma Diagnostics And Therapeutics Market by Drug Class
10.4.6.2 Saudi Arabia Scleroderma Diagnostics And Therapeutics Market
10.4.6.2.1 Saudi Arabia Scleroderma Diagnostics And Therapeutics Market by Type
10.4.6.2.2 Saudi Arabia Scleroderma Diagnostics And Therapeutics Market by Diagnosis
10.4.6.2.3 Saudi Arabia Scleroderma Diagnostics And Therapeutics Market by Drug Class
10.4.6.3 U.A.E Scleroderma Diagnostics And Therapeutics Market
10.4.6.3.1 U.A.E Scleroderma Diagnostics And Therapeutics Market by Type
10.4.6.3.2 U.A.E Scleroderma Diagnostics And Therapeutics Market by Diagnosis
10.4.6.3.3 U.A.E Scleroderma Diagnostics And Therapeutics Market by Drug Class
10.4.6.4 Rest of Middle East and Africa Scleroderma Diagnostics And Therapeutics Market
10.4.6.4.1 Rest of Middle East and Africa Scleroderma Diagnostics And Therapeutics Market by Type
10.4.6.4.2 Rest of Middle East and Africa Scleroderma Diagnostics And Therapeutics Market by Diagnosis
10.4.6.4.3 Rest of Middle East and Africa Scleroderma Diagnostics And Therapeutics Market by Drug Class
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Scleroderma Diagnostics And Therapeutics Market Overview
10.5.2 South and Central America Scleroderma Diagnostics And Therapeutics Market Forecasts and Analysis
10.5.3 South and Central America Scleroderma Diagnostics And Therapeutics Market Forecasts and Analysis - By Type
10.5.4 South and Central America Scleroderma Diagnostics And Therapeutics Market Forecasts and Analysis - By Diagnosis
10.5.5 South and Central America Scleroderma Diagnostics And Therapeutics Market Forecasts and Analysis - By Drug Class
10.5.6 South and Central America Scleroderma Diagnostics And Therapeutics Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Scleroderma Diagnostics And Therapeutics Market
10.5.6.1.1 Brazil Scleroderma Diagnostics And Therapeutics Market by Type
10.5.6.1.2 Brazil Scleroderma Diagnostics And Therapeutics Market by Diagnosis
10.5.6.1.3 Brazil Scleroderma Diagnostics And Therapeutics Market by Drug Class
10.5.6.2 Argentina Scleroderma Diagnostics And Therapeutics Market
10.5.6.2.1 Argentina Scleroderma Diagnostics And Therapeutics Market by Type
10.5.6.2.2 Argentina Scleroderma Diagnostics And Therapeutics Market by Diagnosis
10.5.6.2.3 Argentina Scleroderma Diagnostics And Therapeutics Market by Drug Class
10.5.6.3 Rest of South and Central America Scleroderma Diagnostics And Therapeutics Market
10.5.6.3.1 Rest of South and Central America Scleroderma Diagnostics And Therapeutics Market by Type
10.5.6.3.2 Rest of South and Central America Scleroderma Diagnostics And Therapeutics Market by Diagnosis
10.5.6.3.3 Rest of South and Central America Scleroderma Diagnostics And Therapeutics Market by Drug Class
11. IMPACT OF COVID-19 PANDEMIC ON GLOBAL SCLERODERMA DIAGNOSTICS AND THERAPEUTICS MARKET
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Middle East and Africa
11.5 South and Central America
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. SCLERODERMA DIAGNOSTICS AND THERAPEUTICS MARKET, KEY COMPANY PROFILES
13.1. F. HOFFMANN LA ROCHE LTD.
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. MERCK KGAA
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. PFIZER, INC.
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. BAYER AG
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. BRISTOL-MYERS SQUIBB
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. BIOLINERX, LTD.
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. ACTIVE BIOTECH AB
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. ANGION BIOMEDICA
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. QIAGEN N.V.
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. ACTELION PHARMACEUTICALS, INC.
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
The List of Companies

1. F. Hoffmann La Roche Ltd.
2. Merck KGaA
3. Pfizer, Inc.
4. Bayer AG
5. Bristol-Myers Squibb
6. BioLineRx, Ltd.
7. Active Biotech AB
8. Angion Biomedica
9. QIAGEN N.V.
10. Actelion Pharmaceuticals, Inc.
TIPRE00019755
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking